Table 2. Histopathological subtypes and VEGFR2 IHC immunoreactivity in a multi-tissue screening TMA cohort, n = 50.
| Organ | Diagnosis | n | VEGFR2 vessel pos | VEGFR2 tumor cell pos |
| Brain | Glioblastoma multiforme | 2 | 2 | 0 |
| Breast | All types | 11 | 10 | 10 |
| Ductal carcinoma | 8 | 8 | 8 | |
| Lobular carcinoma | 3 | 2 | 2 | |
| Cervix | Squamous cell carcinoma | 2 | 1 | 2 |
| Colon | Adenocarcinoma | 5 | 5 | 1 |
| Kidney | Renal cell carcinoma | 4 | 4 | 0 |
| Larynx | Squamous cell carcinoma | 4 | 4 | 3 |
| Liver | Hepatocellular carcinoma | 5 | 5 | 0 |
| Lung | All types | 8 | 8 | 2 |
| Adenocarcinoma | 3 | 3 | 0 | |
| Squamous cell carcinoma | 3 | 3 | 2 | |
| Large cell carcinoma | 2 | 2 | 0 | |
| Ovary | Serous carcinoma, ductal adenocarcinoma, and clear cell type | 5 | 4 | 1 |
| Pancreas | Ductal adenocarcinoma or mucinous adenocarcinoma | 4 | 3 | 2 |
Pos, immunopositivity.